semaglutide mash Significantly Improves Steatohepatitis, Fibrosis in Phase III Trial GLP-1 therapies: a new frontier

On the other hand, although statistical significance was not reached, the use of GLP-1RAs showed a trend towards a reduced risk of nine respiratory diseases (pneumonia, pulmonary fibrosis, dyspnea, acute respiratory failure, pleural effusion, COPD, sleep apnea syndrome, and pulmonary embolism)

And in the extension phase out to 104 weeks, the highest dose arm exceeded 30% weight reduction

"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis." N Engl J Med

By targeting additional pathways beyond GLP-1, retatrutide may provide more comprehensive appetite suppression and metabolic effects

The positive effects extend to cardiovascular, metabolic, and mental health, which are often overlooked when the focus is solely on the number on the scale or BMI. Other medical conditions that GLP-1 RAs may exacerbate include gastroparesis and diabetic retinopathy, Chadha noted